Optimization of follow up in prostate cancer active surveillance;Optimización del seguimiento de cáncer de próstata en vigilancia activa

Archivos Espanoles de Urologia

Volumn 67, Issue 5, 2014, Pages 442-451

  Domènech, Ana Celma ^a   Morin, Jacques Planas ^a   Robles, Juan Morote ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Active surveillance; Optimization; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

FEMALE; HUMAN; MALE; PATIENT SELECTION; PROSTATIC NEOPLASMS; WATCHFUL WAITING;

BIOMARKERS, TUMOR; FEMALE; HUMANS; MALE; PATIENT SELECTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; WATCHFUL WAITING;

EID: 84902799166     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Klotz L. Active surveillance for prostate cancer: Overview and update. Current treatment options in oncology. 2013; 14: 97-108.
2. Savage CJ, Lilja H, Cronin AM, Ulmert D, Vickers AJ. Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening. Cancer Epidemiol Biomarkers Prev. 2010; 19: 1201-1207.
3. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol. 1995; 154: 131-138.
4. Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, et al. Insignificant prostate cancer and active surveillance: From definition to clinical implications. Eur Urol, 2009; 55: 1321-1332.
5. Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer. 2008; 112: 1650-1659.
6. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994; 271: 368-374.
7. Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M.Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int. 2008; 101: 165-169.
8. Van As NJ, Norman AR, Thomas K, Khoo VS, Thompson A, Huddart RA, et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. European urology. 2008; 54: 1297-1305.
9. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol, 2010; 28(1): 126-131.
10. Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol, 2010; 58: 831-835.
11. Khatami A, Aus G, Damber JE, Lilja H, Lodding P, Hugosson J. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer. 2007; 120:170-174.
12. Stephenson AJ, Jones JS, Hernandez AV, Ciezki JP, Gong MC, Klein EA. Analysis of T1c prostate cancers treated at very low prostate-specific antigen levels. Eur Urol, 2009; 55:610-616.
13. Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, et al. Active surveillance for low-risk prostate cancer worldwide: The PRIAS study. Eur Urol, 2013; 63(4): e45-e58.
14. Vickers AJ, Savage C, O'Brien MF, Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol. 2009; 27:398-403.
15. O'Brien MF, Cronin AM, Fearn PA, Smith B, Stasi J, Guillonneau B, et al. Pretreatment prostate specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol. 2009; 27: 3591-3597.
16. Loblaw A, Zhang L, Lam A, Nam R, Mamedov A, Vesprini D, et al. Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance. J Urol. 2010; 184: 1942- 1946.
17. Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, et al. Prostate specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol, 2010; 28: 2810-2816.
18. Corcoran NM, Casey RG, Hong MKH, Pedersen J, Connolly S, Peters J, et al. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing grade due to reduced PSA secretion per unit tumour volumen. BJU Int. 2011; 110, 36-42.
19. Magheli A, Hinz S, Hege C, Stephan C, Jung K, Miller K, et al. Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience. J Urol. 2010; 183: 126-131.
20. Venkitaraman R, Norman A, Woode-Amissah R, Fisher C, Dearnaley D, Horwich A, et al. Predictors of histological disease progression in untreated, localized prostate cancer. J Urol, 2007; 178: 833-837.
21. Van Poppel H, Haese A, Graefen M, de la Taille A, Irani J, de Reijke T, et al. The relationship between prostate cancer gene 3 (PCA3) and prostate cancer significance. BJU Int. 2011; 109: 360-366.
22. Shapiro RH, Johnstone PAS. Risk of Gleason grade inaccuracies in prostate cancer patients eligible for active surveillance. Urol, 2012; 80(3): 661-666.
23. Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasarainen H, Bangma CH, et al. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int. 2012; 110(11):1672-1677.
24. Berglund RK, Masterson TA, Vora KC, Eggener SE, Eastham JA, Guillonneau BD. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol. 2008; 180: 1964-1968.
25. Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol. 2007; 178 (6): 2359-2364.
26. Wolters T, Roobol MJ, van Leeuwen PJ, van den Bergh RCN, Hoedemaeker RF, van Leenders GJLH, et al. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol. 2011; 185(1): 121-125.
27. Leibovici D, Shikanov S, Gofrit ON, Zagaja GP, Shilo Y, Shalhav AL. How accurate is our clinical Prediction of "minimal Prostate cancer"?. Isr Med Assoc J. 2013;15(7):359-363.
28. Brannan AJ, Johnstone PAS. The role of tumor volume on outcome in prostate cancer after prostatectomy. Br J Med Surg Urol. 2009; 2:233-237.
29. Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, et al. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol. 2011; 29: 2795-2800.
30. Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, Porten SP, et al. Outcomes of active surveillance for men with intermediate risk prostate cancer. J Clin Oncol. 2011; 29(2): 228-234.
31. Harnden P, Shelley MD, Coles B, Staffurth J, Mason MD. Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis. Lancet Oncol. 2007; 8 (5): 411-419.
32. Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ, Epstein JI, et al. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol. 2010; 183(2): 534-538.
33. Hessels D, van Gils MP, van Hooij O, Jannink SA, Witjes JA, Verhaegh GW, et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate. 2010; 70(1): 10-16.
34. Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol. 2008; 179(5): 1804-1809.
35. Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol. 2008; 180(5): 1975-1978.
36. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, et al. A Multi-Center Study of [-2]Pro-Prostate-Specific Antigen (PSA) in Combination with PSA and Free PSA for Prostate Cancer Detection in the 2.0 to 10.0 ng/mL PSA Range. J Urol. 2011; 185(5): 1650-1655.
37. Isharwal S, Makarov DV, Sokoll LJ, Landis P, Marlow C, Epstein JI, et al. ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. Urol, 2011; 77(3): 763 e761-e766.
38. Ferro M, Bruzzese D, Perdona S, Marino A, Mazzarella C, Perruolo G, et al. Prostate health index (Phi) and prostate cancer antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. PLoS ONE. 2013; 8(7): e67687.
39. Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. The Lancet Oncology. 2011; 12 (3): 245-255.
40. Cuzick J, Berney DM, Fisher G, Mesher D, Müller H, Reid JE, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. British Journal of Cancer. 2012; 106: 1095-1099.
41. Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. JCO. 2013; 31(11): 1428-1434.
42. Aydin H, Kizilgöz V, Tatar IG, Damar C, Ugan AR, Paker I, et al. Detection of prostate cancer with magnetic resonance imaging: optimization of T1-weighted, T2-weighted, dynamic-enhanced T1-weighted, diffusion-weighted imaging apparent diffusion coefficient mapping sequences and MR spectroscopy, correlated with biopsy and histopathological findings. J Comput Assist Tomogr. 2012; 36(1): 30-45.
43. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, et al. ESUR prostate MR guidelines 2012. J. Eur Radiol. 2012; 22:746-757.
44. Padhani A.R. Integrating multiparametric prostate MRI into clinical practice. Cancer Imaging. 2011; 11: S27-S37.